Hadia Khanani

Chris O’Brien Lifehouse

Papers

1

Total Citations

2

H-Index

1

About

Dr. Hadia Khanani is a clinical researcher whose work focuses on advancing surgical oncology, particularly in the management of high-risk prostate cancer. Her primary research area involves refining the role of extended pelvic lymph node dissection (ePLND) in prostate cancer treatment, with an emphasis on trial design and feasibility. Her most notable contribution is the development of the NODE Trial protocol, a prospective multicentre randomised study that tests whether a larger-scale trial of ePLND can achieve adequate recruitment rates. This pilot work is critical for establishing evidence-based standards in lymph node staging for high-risk patients. While her citation count is still growing—with her key 2021 protocol paper garnering 2 citations—the study’s design has laid foundational groundwork for future multicentre collaborations. Dr. Khanani’s research addresses a significant gap in urologic oncology by evaluating both intraoperative and postoperative outcomes, including protocol violations, which are essential for ensuring trial integrity. Her meticulous approach to feasibility studies demonstrates a commitment to rigorous, reproducible surgical research.

Research Focus

Key Achievements

1
H-Index
1
Papers
2
Total Citations
2
Avg Citations/Paper
🏆 Most Cited Paper
Protocol for a Pilot Study of the NODE Trial, a Prospective Multicentre Randomised Trial of Extended Pelvic Lymph Node Dissection for High-Risk Prostate Cancer
2 citations · 2021
📈 Most Prolific Year: 2021 (1 Papers)
🤝 Key Collaborators: 7
🏛 Institutions: Chris O’Brien Lifehouse

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 12 days ago